missing translation for 'onlineSavingsMsg'
Learn More
Learn More
MMP-2 Antibody (2C1), Alexa Fluor™ 750, Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NB200-113AF750
This item is not returnable.
View return policy
Description
MMP-2 Monoclonal specifically detects MMP-2 in Human, Mouse, Rat, Guinea Pig samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.
Specifications
| MMP-2 | |
| Monoclonal | |
| Alexa Fluor 750 | |
| 50 mM sodium borate with 0.05% sodium azide | |
| MMP2 | |
| Activated recombinant human MMP2. [UniProtNo. P08253] | |
| 0.1 mL | |
| Primary | |
| This is specific for pro and active MMP-2. | |
| Store at 4°C in the dark. |
| Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
| 2C1 | |
| Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen | |
| 72 kDa gelatinase, CLG4, CLG4A72 kDa type IV collagenase, collagenase type IV-A, EC 3.4.24, EC 3.4.24.24, Gelatinase A, matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IVcollagenase), matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IVcollagenase), Matrix metalloproteinase-2, matrix metalloproteinase-II, MMP-2, MMP-II, MONA, neutrophil gelatinase, TBE-1matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IVcollagenase) | |
| Mouse | |
| Protein G purified | |
| Angiogenesis, Apoptosis, Cancer, Cell Biology, Cytoskeleton Markers, Extracellular Matrix, HIF Target Genes, Hypoxia, Metastasis, Tumor Suppressors | |
| 4313.0 | |
| Human, Mouse, Rat, Guinea Pig | |
| IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction